Asian drug market stocks slides: Trump’s 100% pharmaceutical tariffs shake market; broader impact on Japan likely minimal
The Times Of India·2025-09-26 06:59
Representative imageCompanies without existing US manufacturing plants could face the full impact, triggering declines across major drugmakers in South Korea, Japan, and Hong Kong.In South Korea, Samsung Biologics fell 1.6%, while SK Biopharmaceuticals slid 2.6%. Celltrion, which recently acquired ImClone Systems from Eli Lilly in the United States for $330 million, rose 1.3% after recouping earlier losses.In Japan, Sumitomo Pharma tumbled 4.3%, Otsuka Holdings dropped 3.5%, and Daiichi Sankyo lost 1.6%. Ta ...